Shanghai Junshi Biosciences Co., Ltd.

SEHK:1877 Stock Report

Market Cap: HK$31.9b

Shanghai Junshi Biosciences Valuation

Is 1877 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of 1877 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: 1877 (HK$15.37) is trading below our estimate of future cash flow value (HK$57.11)

Significantly Below Future Cash Flow Value: 1877 is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 1877?

Key metric: As 1877 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 1877. This is calculated by dividing 1877's market cap by their current revenue.
What is 1877's PS Ratio?
PS Ratio5x
SalesCN¥2.72b
Market CapCN¥27.65b

Price to Sales Ratio vs Peers

How does 1877's PS Ratio compare to its peers?

The above table shows the PS ratio for 1877 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average5.7x
2315 Biocytogen Pharmaceuticals (Beijing)
10.3x22.45%HK$41.4b
1530 3SBio
2x-13.84%HK$40.2b
2696 Shanghai Henlius Biotech
4.2x8.23%HK$32.3b
9969 InnoCare Pharma
6.3x14.47%HK$23.4b
1877 Shanghai Junshi Biosciences
5x20.80%HK$31.9b

Price-To-Sales vs Peers: 1877 is good value based on its Price-To-Sales Ratio (5x) compared to the peer average (5.6x).

Historical Price to Sales Ratio

Historical Price to Sales Ratio compares a stock's price to its sales over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Sales Ratio vs Industry

How does 1877's PS Ratio compare vs other companies in the HK Biotechs Industry?

20 CompaniesPrice / SalesEstimated GrowthMarket Cap
1530 3SBio
2x-13.84%US$5.12b
2696 Shanghai Henlius Biotech
4.2x8.23%US$4.11b
6185 CanSino Biologics
4.1x23.08%US$1.20b
1952 Everest Medicines
4.3x22.74%US$1.08b
1877 5.0xIndustry Avg. 10.3xNo. of Companies20PS020406080100+
20 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 1877 is good value based on its Price-To-Sales Ratio (5x) compared to the Hong Kong Biotechs industry average (10.3x).

Price to Sales Ratio vs Fair Ratio

What is 1877's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1877 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio5x
Fair PS Ratio10x

Price-To-Sales vs Fair Ratio: 1877 is good value based on its Price-To-Sales Ratio (5x) compared to the estimated Fair Price-To-Sales Ratio (10x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 1877 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentHK$15.37
HK$29.91
+94.59%
18.97%HK$35.31HK$20.37n/a4
Jun ’27HK$19.35
HK$29.90
+54.52%
18.98%HK$35.29HK$20.36n/a4
May ’27HK$26.32
HK$29.74
+13.00%
19.09%HK$34.92HK$20.14n/a4
Apr ’27HK$25.84
HK$30.95
+19.77%
21.88%HK$38.59HK$20.03n/a4
Mar ’27HK$20.48
HK$32.06
+56.55%
22.49%HK$38.62HK$20.00n/a4
Feb ’27HK$21.38
HK$31.68
+48.19%
21.20%HK$37.91HK$20.49n/a4
Jan ’27HK$21.34
HK$30.99
+45.22%
21.20%HK$37.08HK$20.04n/a4
Dec ’26HK$24.78
HK$30.99
+25.06%
21.20%HK$37.08HK$20.04n/a4
Nov ’26HK$26.58
HK$30.89
+16.23%
21.20%HK$36.97HK$19.98n/a4
Oct ’26HK$30.46
HK$30.36
-0.32%
24.30%HK$36.91HK$17.96n/a4
Sep ’26HK$32.98
HK$28.97
-12.16%
27.68%HK$36.97HK$18.01n/a3
Aug ’26HK$24.55
HK$21.12
-13.97%
38.92%HK$32.00HK$12.13n/a3
Jul ’26HK$20.75
HK$16.09
-22.45%
18.38%HK$19.17HK$12.10n/a3
Jun ’26HK$20.20
HK$16.09
-20.33%
18.53%HK$19.01HK$12.00HK$19.353
May ’26HK$16.34
HK$15.67
-4.08%
21.55%HK$18.88HK$11.00HK$26.323
Apr ’26HK$16.32
HK$15.67
-3.96%
21.55%HK$18.88HK$11.00HK$25.843
Mar ’26HK$15.04
HK$15.53
+3.29%
21.66%HK$18.72HK$10.88HK$20.483
Feb ’26HK$11.00
HK$15.61
+41.92%
21.60%HK$18.87HK$10.97HK$21.383
Jan ’26HK$11.58
HK$15.38
+32.81%
20.83%HK$18.57HK$11.00HK$21.343
Dec ’25HK$13.22
HK$15.38
+16.34%
20.83%HK$18.57HK$11.00HK$24.783
Nov ’25HK$12.72
HK$15.84
+24.54%
18.12%HK$18.80HK$11.95HK$26.583
Oct ’25HK$15.70
HK$14.58
-7.14%
16.78%HK$17.03HK$12.13HK$30.462
Sep ’25HK$11.90
HK$14.42
+21.18%
17.11%HK$16.89HK$11.95HK$32.982
Aug ’25HK$12.36
HK$14.42
+16.67%
17.11%HK$16.89HK$11.95HK$24.552
Jul ’25HK$11.70
HK$17.30
+47.85%
26.28%HK$23.06HK$11.95HK$20.753
Jun ’25HK$12.34
HK$24.71
+100.27%
45.45%HK$45.52HK$12.02HK$20.206
HK$29.91
Fair Value
48.6% undervalued intrinsic discount
4
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/26 09:27
End of Day Share Price 2026/06/26 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Shanghai Junshi Biosciences Co., Ltd. is covered by 16 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jin ZhangChina International Capital Corporation Limited
Congmin YuanCitic Securities Co., Ltd.
Muk Tsz YungCitigroup Inc